Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

109.85 +1.12 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 503,456
Open 108.69
Bid (Size) 108.50 (2)
Ask (Size) 110.50 (10)
Prev. Close 108.73
Today's Range 107.25 - 110.47
52wk Range 100.08 - 188.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
Benzinga 
Via Benzinga
Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants
Novavax Inc's (NASDAQ: NVAX) R&D chief Filip Dubovsky expressed confidence that the company's updated COVID-19 vaccine, already in production, will offer protection against the rapidly emerging... 
Via Benzinga

Performance

YTD
-26.10%
-26.10%
1 Month
+1.67%
+1.67%
3 Month
-16.49%
-16.49%
6 Month
-34.11%
-34.11%
1 Year
-31.05%
-31.05%

More News

Read More
3 Ugly Stocks That Actually Hide Beautiful Potential
Via InvestorPlace
Why Shares of BioNTech Rose Friday
Via The Motley Fool
The Latest Analyst Ratings for BioNTech
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
What To Know About Redburn Partners's Upgrade of BioNTech
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
Via Investor's Business Daily
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
From BioNTech SE
Via GlobeNewswire
7 Deeply Undervalued Growth Stocks to Buy in June
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Expert Ratings for BioNTech
Via Benzinga
BioNTech Se (BNTX) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Via Benzinga
Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
Via Benzinga
Why Pfizer Stock Slipped by 2% Today
Via The Motley Fool
BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases
Via Benzinga
As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction
Via Benzinga
Why Novavax, Pfizer And BioNTech Shares Are Rising Today
Via Benzinga
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
Via The Motley Fool
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
Via Benzinga
Palo Alto Networks To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2023
Via Benzinga
Why Matinas BioPharma Stock Is Sinking Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.